Implicit Bioscience Company
Implicit Bioscience holds worldwide rights to IC14 and is developing it in the new field of immunoneurology for a range of neurodegenerative and neurotraumatic disease indications.
Technology:
Drug Delivery
Industry:
Genomic and Epigenominc Instabillity
Headquarters:
Australia
Founded Date:
2004
Employees Number:
11-50
Estimated Revenue:
Less than $1M
Register and Claim Ownership